Clinical Trial Update: Prevention of Irinotecan Induced Diarrhea by Probiotics [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating a probiotic therapy to prevent irinotecan-induced diarrhea in colorectal cancer patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Probiotic therapy to prevent irinotecan-induced diarrhea

Snippet

Sponsor: Monsea Ltd. | Conditions: Colorectal Cancer | Phase 3 | Status: COMPLETED